Jesper Breum

Jesper Breum, MSc, is Chief Quality Officer and co-founder of TETRAPHARM, a Danish biopharmaceutical company founded in 2018 with Martin Rose. The company focuses on pharmaceutical drugs targeting the central nervous system and immune system to treat neurological diseases and mental health disorders.

Prior to founding TETRAPHARM, Jesper's professional career of more than 20 years spanned senior roles within the pharmaceutical industry, including at Biogen, CMC Biologics and Bioneer. Before this, Breum worked in the pharmaceutical industry for 15 years in R&D, Project Management, Sourcing, Quality Assurance, and Business Development & Strategy for Lundbeck, Novo Nordisk and Niels Clauson-Kaas. He was CEO of venture-backed diagnostics company ilochip A/S before joining Lundbeckfonden Ventures as Senior Partner for 12 years, where he led investments and board roles in companies including Sanifit, Aura Biosciences, Spero Therapeutics, Nexstim, and Biomup.

Career History

• Chief Quality Officer & Co-founder, TETRAPHARM (2018–present)
• Senior Partner, Lundbeckfonden Ventures (12 years)
• CEO, ilochip A/S (venture-backed diagnostics)
• Senior roles at Biogen, CMC Biologics, and Bioneer (pharmaceutical industry)
• Various roles in R&D, Project Management, Sourcing, QA, and Business Development at Lundbeck, Novo Nordisk (15 years)

Education and Expertise: Breum holds an MSc in organic chemistry and an Executive MBA, both from the Technical University of Denmark. While at Lundbeck, he was part of spinning out Veloxis (sold to Asahi Kasei) and served on the board of the Lundbeck Foundation.

What Jesper Breum could bring to new biotech ventures: Breum is pursuing new biotech ventures with co-founder Martin Rose while remaining shareholders in TETRAPHARM. His unique combination of deep pharmaceutical R&D expertise, quality assurance and CMC (chemistry, manufacturing, controls) experience, venture capital investment acumen, and successful track record scaling biotech companies from early-stage through commercialization positions him to identify and develop high-potential therapeutic opportunities in complex areas like cannabinoid-based medicines and CNS disorders.